【摘要】 目的研究重组人肿瘤坏死因子在腹腔恶性积液首次治疗中的应用效果。方法选取病历资料完整的腹腔恶性积液患者60例,录入计算机随机对照系统分为观察组和对照组,每组30例,观察组采用重组人肿瘤坏死因子+深部热疗治疗,对照组则采用灌注化疗+深部热疗;比较两组疗程结束后临床效果、生活质量和安全性。结果观察组首次治疗总有效率为73.33%,对照组首次治疗总有效率为46.67%,组间比较,差异有统计学意义(P<0.05);观察组生活质量评分各项因子均高于对照组,组间比较,差异有统计学意义(P<0.01);两组主要不良反应为恶心呕吐、失眠以及腹泻,观察组不良反应轻于对照组,差异有统计学意义(P<0.05)。结论重组人肿瘤坏死因子用于腹腔恶性积液治疗中取得显著成效,耐受性高,安全性高,在临床治疗中有广阔前景。更多还原

【Abstract】 Objective To study the clinical application of recombinant human tumor necrosis factor(rTNF) in the treatment of patients with malignant ascites. Method 60 patients with malignant ascites who had complete medical records were included in the study, and were randomized as study group or control group by computer algorithm, with 30 cases in each, the study group was treated with rTNF combined with deep thermotherapy, while the control group was given perfusion of chemotherapy and deep thermotherapy, the clinical efficacy, quality of life(QOL) and safety in both groups were compared. Result The overall response rate was 73.33% in study group as the primary treatment, and it was 46.67% in control group, with statistically significant differences observed(P<0.05); the study group had generally better QOL scores in each subscale compared with the control group(P<0.01); as for adverse reactions, nausea and vomiting, insomnia, and diarrhea were the main observations, with lower severity in study group than control group(P<0.05).Conclusion Recombinant human tumor necrosis factor is remarkably useful as the primary treatment for malignant ascites, which is a tolerable and safe therapy.更多还原